AbbVie has also submitted an application in the EU ... to be more than $27 billion by 2027 UC is a form of inflammatory bowel disease (“IBD”). Skyrizi’s approval for the UC indication ...

AbbVie has also submitted an application to the FDA, seeking the label expansion for Skyrizi to include the UC indication in the United States. The regulatory filing is yet to be accepted for review.

Drug now approved for four conditions across different inflammatory diseases Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with ...

Inc. ABBV announced that it submitted a regulatory application with the European Medicines Agency (EMA), seeking approval for its interleukin-23 (“IL-23”) inhibitor risankizumab (Skyrizi) as a ...

MONTREAL, March 4, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ...

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...

AbbVie (NYSE:ABBV) added ~1% pre-market Thursday after announcing that its interleukin-23 inhibitor Skyrizi met the primary and all secondary endpoints in a Phase 3 trial for adults with ...